Metabolon Target
Bile Acids Targeted Panel
Absolute Quantitation
Rigorous Quality Control
End-to-end Service
About Bile Acids
Bile acids are derived from cholesterol and serve an important role in emulsifying and digesting lipids. In addition, bile acid metabolism is intimately involved with the microbiota, and bile acids have been shown to exhibit endocrine and metabolic activity via receptors like FXR and TGR5. Metabolon’s Bile Acids Targeted Panel measures all the major human and rodent primary and secondary bile acids as well as their glycine and taurine conjugates.
Metabolomics reveals biological insights otherwise unseen. For a successful metabolomics study, both small molecule discovery and the ability to dig deeper into specific biomarkers of interest are needed to uncover actionable insights that propel new therapeutic developments. A specific combination of liquid chromatography-mass spectrometry (LC-MS) technology and expertise is required to identify these biomarkers of interest and develop assays that are sensitive enough to explore them fully.
At Metabolon, we understand the crucial role targeted small molecule assays play in drug development, and we’ve established best-in-class expertise. Metabolon has developed quantitative assays for more than 900 biochemicals in over 20 different matrices, including more than 150 qualified and/or validated targeted biochemical assays for pharmaceutical and biotechnology research and development. These assays focus on specific metabolites or metabolic pathways and can be used to track biomarkers and enhance biological understanding across preclinical and clinical research.
Bile Acids Targeted Panel Details
Swipe left/right to view the full table.
LLOQa | |||
---|---|---|---|
Metabolite | Serum/Plasma (ng/mL)b | Feces (ng/mg)b | Feces in OMNImet™·GUT tube (µg/g dry feces)c |
Cholic Acid | 2.5 | 0.25 | 0.63 |
Chenodeoxycholic Acid | 5.0 | 0.50 | 0.63 |
Deoxycholic Acid | 5.0 | 0.50 | 0.63 |
Lithocholic Acid | 2.5 | 0.25 | 0.63 |
Ursodeoxycholic Acid | 5.0 | 0.50 | 0.63 |
Glycocholic Acid | 2.5 | 0.25 | 0.13 |
Glycochenodeoxycholic Acid | 5.0 | 0.50 | 0.13 |
Glycodeoxycholic Acid | 2.5 | 0.25 | 0.13 |
Glycoursodeoxycholic Acid | 5.0 | 0.50 | 0.63 |
Taurocholic Acid | 2.5 | 0.25 | 0.63 |
Taurochenodeoxycholic Acid | 5.0 | 0.50 | 0.130 |
Taurodeoxycholic Acid | 5.0 | 0.50 | 0.63 |
Taurolithocholic Acid | 2.5 | 0.25 | 0.63 |
Tauroursodeoxycholic Acid | 2.5 | 0.25 | 0.130 |
Glycolithocholic Acid | 2.5 | 0.25 | 0.63 |
Additional Bile Acids in Rodent Samples | |||
Alpha-Muricholic Acid | 2.5 | 0.25 | |
Beta-Muricholic Acid | 2.5 | 0.25 | |
Omega-Muricholic Acid | 2.5 | 0.25 | |
Gamma-Muricholic Acid | 2.5 | 0.25 | |
Tauro Alpha-Muricholic Acid | 10 | 1.0 | |
Tauro Beta-Muricholic Acid | 10 | 1.0 |
bAssays with this sample type are for non-GxP testing and are not for diagnostic use.
cGood Clinical Practice (GCP) Assays. Lower Limit of Quantitation (LLOQ) stated is based on normalization using an average dry weight of feces. The actual measurement of the assay is the concentration of analyte in the OMNImet™·GUT tube containing human feces. Analyte concentrations in the OMNImet™·GUT tubes will be normalized by measured dry weight of feces unless otherwise requested.
Analysis Method and Instrumentation
LC-MS/MS (Agilent 1290 UHPLC/Sciex QTrap 5500 (GCP) or 6500 or 6500+ (non-GxP testing)
Sample Type and Required Amounts | |
---|---|
Sample Type | Sample Requirement |
Feces (wet/frozen) human | 300 to 400 mg |
Feces (wet/frozen) mouse | 3-5 pellets |
Plasma/Serum (human) | ≥ 150 µl |
Plasma/Serum (mouse) | ≥ 100 µl |
Tissue (liver) | 50 to 100 mg |
Feces in OMNImet™·GUT tube | Entire sample collection tube |
Disclaimer: This panel is for Research Use Only and is not to be used for diagnostic purposes.
Delivering Absolute Quantification for Research and Biomarker Analysis
Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover >1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.
Bile Acids Targeted Panel Applications
Cancer
COVID
Recognized for our cutting-edge approach to metabolomics, Metabolon has been a valued resource for COVID-19 researchers worldwide. Our actionable metabolomic insights have fueled pivotal and high-profile studies like the National Institute of Allergy and Infectious Diseases (NIAID) IMPACC study research to improve understanding of high-risk patients and the Institute for Systems Biology research to improve understanding of high-risk patients. These and other metabolomics projects with actionable insights at Metabolon are helping get closer to the phenotype and pressing forward on COVID-19 answers.
Diabetes
Gut Health
Liver
Neuroscience
Nutrition
Metabolomics can be essential for investigating the association between nutrition and health status, as metabolites represent a functional readout at the interface between diet and the complex metabolic systems that influence both health and disease. By illuminating the interactions of metabolites throughout the body within defined pathways, targeted metabolomics can help investigators gain new insights into the absorption and digestion of diet-derived macronutrients, monitor metabolism by various organ systems, and subsequently assess the underlying biology of various health and disease states.
Big Insights with Metabolon
Cited in over 3,000 publications, we help scientists and manufacturers gain greater insight into their studies through metabolomics. See how our approach can become a successful part of your workflow.
Related Metabolomics Resources
Contact Us
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560